MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10792-026-04178-5

Медицинская библиотека · International ophthalmology · 2026

Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials.

Almutawtah Sara, AlFoudari Yaqoub, Mohammad Ahmed, Ahmad Shahad T, Alanezi Shooq Hussain, Alqussair Farah R, Alfailakawi Abdulrahman, Bonajmah Haidar, Alharran Abdullah M

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

BACKGROUND

Dry eye disease is a multifactorial ocular surface disorder characterized by tear film instability and inflammation, leading to impaired visual function and reduced quality of life. Varenicline solution nasal spray is a nicotinic acetylcholine receptor agonist stimulates the trigeminal pathway to enhance basal tear production.

METHODS

We searched electronic databases (PubMed, Scopus, and Web of Science) from inception to February 2026 to identify randomized controlled trials (RCTs) assessing varenicline nasal spray (0.03 mg or 0.06 mg twice daily) in adults with dry eye symptoms. Primary outcomes included the proportion of patients achieving ≥ 10-mm improvement in Schirmer test score (STS) and mean change in STS. Secondary outcomes included Eye Dryness Score (EDS), corneal fluorescein staining and treatment-emergent adverse events (TEAEs). Meta-analyses were conducted using random-effects models. The primary analysis focused on the approved 0.06 mg dose, with dose-based subgroup analyses comparing 0.03 mg and 0.06 mg doses where data were available.

RESULTS

Seven randomized controlled trials were included. In the primary 0.06 mg analysis, varenicline nasal spray significantly improved mean Schirmer test score change (MD = 5.52 mm; 95% CI: 4.08 to 6.97; p < 0.0001) and increased the proportion of patients achieving a ≥ 10-mm Schirmer test score improvement (RR = 1.86; 95% CI: 1.50 to 2.30; p < 0.0001). Eye Dryness Score showed a non-significant numerical improvement (MD =  - 4.38; 95% CI: - 12.02 to 3.25; p = 0.2601). Dose-based subgroup analyses showed consistent Schirmer test benefits for both 0.03 mg and 0.06 mg doses. Corneal fluorescein staining was not significantly improved. Ocular adverse events and reduced visual acuity were comparable between groups, while non-ocular adverse events, particularly sneezing, were more frequent with varenicline.

CONCLUSIONS

Varenicline nasal spray improved tear production, with less consistent effects on symptoms and corneal staining. Ocular safety was comparable, but sneezing was more frequent.

Для цитирования: Almutawtah Sara, AlFoudari Yaqoub, Mohammad Ahmed, Ahmad Shahad T, Alanezi Shooq Hussain, Alqussair Farah R, Alfailakawi Abdulrahman, Bonajmah Haidar, Alharran Abdullah M. Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials.. International ophthalmology. 2026. DOI: 10.1007/s10792-026-04178-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.